Walgreens to close 1,200 stores as part of turnaround effort
Media

Walgreens to close 1,200 stores as part of turnaround effort

Walgreens plans to close at least 1,200 stores over the next three years as the pharmacy giant seeks to reduce costs and turn around operations under a new leader. 

One of the largest drugstore chains in the country, Walgreens said it was targeting 900 to 1,000 stores primarily across the U.S. by the end of fiscal year 2027, which is part of the company’s “multi-year footprint optimization program.” About 500 stores are slated to close as early as fiscal year 2025.

WALGREENS TO PAY $106.8M OVER CLAIMS IT BILLED GOVERNMENT FOR PRESCRIPTIONS NEVER DISPENSED

In June, the company had announced its intention to close a “significant” number of underperforming stores across the U.S. as it contended with profitability challenges and declining margins. But CEO Tim Wentworth, who took over in October 2023, didn’t give an estimate at the time of how many stores would be affected. He noted that a “meaningful percent” of the underperforming locations would shutter. 

Wentworth said in June that there is a “difficult operating environment, including persistent pressures on the U.S. consumer and the impact of recent marketplace dynamics which have eroded pharmacy margins.”

WALGREENS CUTTING PRICES ON 1,300 PRODUCTS

In its latest earnings report on Tuesday, Wentworth said that the company’s fiscal fourth-quarter and full-year results “reflected our disciplined execution on cost management.” 

Walgreens reported revenue of $37.55 billion for the fiscal fourth quarter, up 6% from the same period a year ago and beating Wall Street estimates of $35.75 billion. 

GET FOX BUSINESS ON THE GO BY CLICKING HERE

The company also reported a net loss of $3 billion, or $3.48 per share, for the quarter. 

Shares of Walgreens Boost Alliance rose more than 4% in premarket trading on Tuesday.

In fiscal 2025, Wentworth said Walgreens plans to focus “on stabilizing the retail pharmacy by optimizing our footprint, controlling operating costs, improving cash flow, and continuing to address reimbursement models to support dispensing margins and preserve patient access for the future.” 

Leave a Reply

Your email address will not be published. Required fields are marked *

This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.